Cerebrovascular Accident

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody

150%

Small Molecule

150%

+ 11 programs with unclassified modality

On Market (3)

Approved therapies currently available

CANDESARTAN CILEXETILApproved

candesartan

Unknown Company

oral2016

DYSPORTApproved

botulinum toxin type a

Ipsen

Acetylcholine Release Inhibitor [EPC]injection2009

REOPROApproved

abciximab

Unknown Company

injection1994

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Boehringer IngelheimINGELHEIM, Germany

5 programs

Aggrenox bidPhase 41 trial

Aggrenox capsulePhase 31 trial

Aggrenox® modified release capsulesPhase 31 trial

rt-PA 0.9 mg/kg verum or placebo IntravenousPhase 31 trial

HippotherapyN/A1 trial

Active Trials

NCT04759326Recruiting52Est. Mar 2026

NCT00311402Completed1,295

NCT00274586Completed100Est. Apr 2003

+2 more trials

IpsenChina - Tianjin

1 program

Botulinum toxin type APhase 41 trial

Active Trials

NCT00216411Completed96Est. Jul 2006

TakedaTOKYO, Japan

1 program

CandesartanPhase 4Small Molecule1 trial

Active Trials

NCT00108706Unknown50Est. Sep 2007

Eli Lilly and CompanyINDIANAPOLIS, IN

2 programs

AbciximabPhase 3Monoclonal Antibody1 trial

atomoxetineN/A1 trial

Active Trials

NCT00634439Completed72,000Est. Sep 2008

NCT00073372Terminated808Est. Dec 2005

WicabWI - Fitchburg

1 program

BrainPort Balance DeviceN/A1 trial

Active Trials

NCT00567944Completed29Est. Apr 2010

CENTOGENEGermany - Rostock

1 program

Fabry and Cardiomyopathy (FaCard)N/A1 trial

Active Trials

NCT01429597Withdrawn0Est. Dec 2019

Mission TherapeuticsUK - Cambridge

1 program

Focus of attentionN/A1 trial

Active Trials

NCT04696302Completed38Est. May 2019

Alliance PharmaceuticalsUK - Wiltshire

1 program

HippotherapyN/A

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Boehringer IngelheimAggrenox bid

TakedaCandesartan

IpsenBotulinum toxin type A

Boehringer IngelheimAggrenox capsule

Eli Lilly and CompanyAbciximab

Boehringer Ingelheimrt-PA 0.9 mg/kg verum or placebo Intravenous

Boehringer IngelheimAggrenox® modified release capsules

Boehringer IngelheimHippotherapy

Mission TherapeuticsFocus of attention

CENTOGENEFabry and Cardiomyopathy (FaCard)

Eli Lilly and Companyatomoxetine

WicabBrainPort Balance Device

Clinical Trials (12)

Total enrollment: 75,840 patients across 12 trials

NCT00562588 Boehringer IngelheimAggrenox bid

EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA

Start: Jul 2007551 patients

Phase 4Completed

NCT00108706 TakedaCandesartan

Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)

Start: Dec 2004Est. completion: Sep 200750 patients

Phase 4Unknown

NCT00216411 IpsenBotulinum toxin type A

Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm

Start: Nov 2004Est. completion: Jul 200696 patients

Phase 4Completed

NCT00311402 Boehringer IngelheimAggrenox capsule

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme

Start: Apr 20061,295 patients

Phase 3Completed

NCT00073372 Eli Lilly and CompanyAbciximab

A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)

Start: Oct 2003Est. completion: Dec 2005808 patients

Phase 3Terminated

NCT00153036 Boehringer Ingelheimrt-PA 0.9 mg/kg verum or placebo Intravenous

Rt-PA in the Treatment of Acute Ischemic Stroke

Start: Apr 2003821 patients

Phase 3Completed

NCT00274586 Boehringer IngelheimAggrenox® modified release capsules

Headache Study to Compare Aggrenox Full Dose and Reduced Dose

Start: Sep 2002Est. completion: Apr 2003100 patients

Phase 3Completed

NCT04759326 Boehringer IngelheimHippotherapy

Neurorehabilitation Through Hippotherapy of a Brain Stroke

Start: Apr 2022Est. completion: Mar 202652 patients

N/ARecruiting

NCT04696302 Mission TherapeuticsFocus of attention

Focus of Attention in Individuals With Stroke

Start: Mar 2015Est. completion: May 201938 patients

N/ACompleted

NCT01429597 CENTOGENEFabry and Cardiomyopathy (FaCard)

Fabry and Cardiomyopathy (FaCard)

Start: Jul 2011Est. completion: Dec 20190

N/AWithdrawn

NCT00634439 Eli Lilly and Companyatomoxetine

Safety Study of Atomoxetine and Cerebrovascular Outcomes

Start: Jan 2008Est. completion: Sep 200872,000 patients

N/ACompleted

NCT00567944 WicabBrainPort Balance Device

Use of the BrainPort® Balance Device to Improve Balance in Adults With Balance Deficits Due to Stroke

Start: Jun 2007Est. completion: Apr 201029 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals

1 actively recruiting trials targeting 75,840 patients

8 companies competing in this space